Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
2.58 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 1.436 | 1.697 |
| Cost of Revenue
| 0.184 | 0.169 | 0.004 | 0.008 | 0.009 |
| Gross Profit
| -0.184 | -0.169 | -0.004 | 1.428 | 1.688 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0.994 | 0.995 |
| Reseach & Development Expenses
| 42.318 | 32.361 | 12.305 | 7.997 | 8.576 |
| General & Administrative Expenses
| 18.82 | 12.876 | 7.279 | 1.351 | 0.926 |
| Selling & Marketing Expenses
| -0.184 | 0 | 0 | 0 | 0 |
| SG&A
| 18.636 | 12.876 | 7.279 | 1.351 | 0.926 |
| Other Expenses
| 0 | -0.011 | 0.051 | 0 | 0 |
| Operating Expenses
| 60.954 | 45.237 | 19.584 | 9.348 | 9.502 |
| Operating Income
| -61.138 | -45.237 | 61.573 | -7.912 | -7.805 |
| Operating Income Ratio
| 0 | 0 | 0 | -5.51 | -4.599 |
| Total Other Income Expenses Net
| 8.767 | 2.381 | -162.179 | 0.587 | -0.102 |
| Income Before Tax
| -52.371 | -42.856 | -100.606 | -7.325 | -7.907 |
| Income Before Tax Ratio
| 0 | 0 | 0 | -5.101 | -4.659 |
| Income Tax Expense
| 0 | -2.381 | 81.073 | -0.001 | -0.045 |
| Net Income
| -52.371 | -40.475 | -181.679 | -7.324 | -7.862 |
| Net Income Ratio
| 0 | 0 | 0 | -5.1 | -4.633 |
| EPS
| -1.08 | -1 | -4.49 | -0.18 | -0.2 |
| EPS Diluted
| -1.08 | -1 | -4.49 | -0.18 | -0.2 |
| EBITDA
| -60.954 | -45.068 | 61.577 | -8.498 | -7.658 |
| EBITDA Ratio
| 0 | 0 | 0 | -5.918 | -4.513 |